ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - FRA:ZEG - GB0009895292 - Common Stock
141.95 EUR
-0.65 (-0.46%)
We assign a fundamental rating of 5 out of 10 to ZEG. ZEG was compared to 52 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are concerns on its financial health. While showing a medium growth rate, ZEG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
ZEG had a positive operating cash flow in the past year.
In the past 5 years ZEG has always been profitable.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ZEG (7.38%) is comparable to the rest of the industry.
ZEG has a Return On Equity of 18.55%. This is in the better half of the industry: ZEG outperforms 61.54% of its industry peers.
The Return On Invested Capital of ZEG (14.26%) is better than 73.08% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ZEG is below the industry average of 15.23%.
The last Return On Invested Capital (14.26%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.38% | ||
| ROE | 18.55% | ||
| ROIC | 14.26% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
ZEG has a Profit Margin of 14.68%. This is comparable to the rest of the industry: ZEG outperforms 59.62% of its industry peers.
ZEG's Profit Margin has improved in the last couple of years.
ZEG has a better Operating Margin (24.39%) than 61.54% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 82.07%, ZEG belongs to the top of the industry, outperforming 82.69% of the companies in the same industry.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.39% | ||
| PM (TTM) | 14.68% | ||
| GM | 82.07% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
ZEG has more shares outstanding than it did 5 years ago.
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.50 indicates that ZEG is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZEG (5.50) is better than 75.00% of its industry peers.
ZEG has a debt to FCF ratio of 4.01. This is a neutral value as ZEG would need 4.01 years to pay back of all of its debts.
The Debt to FCF ratio of ZEG (4.01) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.63 indicates that ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.63) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 4.01 | ||
| Altman-Z | 5.5 |
ROIC/WACC1.59
WACC8.98%
2.3 Liquidity
A Current Ratio of 0.86 indicates that ZEG may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.86, ZEG is doing worse than 78.85% of the companies in the same industry.
ZEG has a Quick Ratio of 0.86. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ZEG (0.67) is worse than 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.30% over the past year.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
ZEG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.00%.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)22.3%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%9.6%
Revenue 1Y (TTM)15%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.44% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.04% on average over the next years.
EPS Next Y13.74%
EPS Next 2Y13.62%
EPS Next 3Y12.75%
EPS Next 5Y12.44%
Revenue Next Year9.63%
Revenue Next 2Y7.79%
Revenue Next 3Y7.1%
Revenue Next 5Y7.04%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.56, the valuation of ZEG can be described as rather expensive.
ZEG's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 26.10. ZEG is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 15.47, the valuation of ZEG can be described as correct.
ZEG's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.52. ZEG is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.56 | ||
| Fwd PE | 15.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than 65.38% of the companies in the same industry.
ZEG's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 63.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.11 | ||
| EV/EBITDA | 25.93 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ZEG's earnings are expected to grow with 12.75% in the coming years.
PEG (NY)1.35
PEG (5Y)1
EPS Next 2Y13.62%
EPS Next 3Y12.75%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.95%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.98, ZEG has a dividend in line with its industry peers.
ZEG's Dividend Yield is comparable with the S&P500 average which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.95% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 59.51% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP59.51%
EPS Next 2Y13.62%
EPS Next 3Y12.75%
FRA:ZEG (10/31/2025, 7:00:00 PM)
141.95
-0.65 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap440.12B
Revenue(TTM)56.50B
Net Income(TTM)8.29B
Analysts81.82
Price Target156.83 (10.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.95% |
Yearly Dividend2.58
Dividend Growth(5Y)1.4%
DP59.51%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.79%
Min EPS beat(2)-1.74%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)1.17%
EPS beat(12)8
Avg EPS beat(12)2.95%
EPS beat(16)11
Avg EPS beat(16)2.52%
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)-0.24%
Revenue beat(4)2
Avg Revenue beat(4)-0.14%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)7
Avg Revenue beat(16)0.32%
PT rev (1m)-1.13%
PT rev (3m)-1.09%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)3.34%
EPS NY rev (1m)0%
EPS NY rev (3m)1.12%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)0.89%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.56 | ||
| Fwd PE | 15.47 | ||
| P/S | 9 | ||
| P/FCF | 62.11 | ||
| P/OCF | 37.97 | ||
| P/B | 11.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.93 |
EPS(TTM)7.65
EY5.39%
EPS(NY)9.18
Fwd EY6.46%
FCF(TTM)2.29
FCFY1.61%
OCF(TTM)3.74
OCFY2.63%
SpS15.78
BVpS12.49
TBVpS-4.03
PEG (NY)1.35
PEG (5Y)1
Graham Number46.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.38% | ||
| ROE | 18.55% | ||
| ROCE | 17.47% | ||
| ROIC | 14.26% | ||
| ROICexc | 15.63% | ||
| ROICexgc | 78.69% | ||
| OM | 24.39% | ||
| PM (TTM) | 14.68% | ||
| GM | 82.07% | ||
| FCFM | 14.48% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 4.01 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 76.24% | ||
| Cap/Sales | 9.21% | ||
| Interest Coverage | 10.19 | ||
| Cash Conversion | 64.97% | ||
| Profit Quality | 98.66% | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.67 | ||
| Altman-Z | 5.5 |
F-Score7
WACC8.98%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)22.3%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%9.6%
EPS Next Y13.74%
EPS Next 2Y13.62%
EPS Next 3Y12.75%
EPS Next 5Y12.44%
Revenue 1Y (TTM)15%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.74%
Revenue Next Year9.63%
Revenue Next 2Y7.79%
Revenue Next 3Y7.1%
Revenue Next 5Y7.04%
EBIT growth 1Y37.03%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y12.9%
FCF growth 1Y24.74%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y31.54%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 18.56 and the Price/Book (PB) ratio is 11.37.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.